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Hereditary hemorrhagic telangiectasia (HHT) is an inherited disease caused by impaired 
signaling through the bone morphogenetic protein (BMP) receptor, ALK1, and is characterized by 
fragile, direct connections between arteries and veins, called arteriovenous malformation (AVMs). 
AVMs can form in skin, mucous membranes, brain, lung, and liver and can be life-threatening if 
severe shunting or rupture occurs. For example, severe liver AVMs result in low systemic vascular 
resistance, which can lead to a transient, compensatory high-output cardiac state followed by 
decompensation and heart failure. The only treatment for HHT-associated high-output heart failure 
(HOHF) is liver transplant. As such, the need for targeted therapeutics is clear, yet little is known 
about the pathological progression of HOHF. Here, I describe zebrafish bmp10 mutants as a useful 
animal model of HHT-associated, age-dependent HOHF. bmp10 encodes one of three Alk1 ligands 
in zebrafish, and homozygous bmp10 mutants develop dilated and hemorrhagic skin vessels, 
edema, and enlarged hearts as early as six weeks of age. bmp10 mutants with severe early-onset 
vascular phenotype exhibit high cardiac output, cardiomyocyte (CM) disorganization, and early 
death, whereas those with later-onset vascular lesions show milder heart phenotype. At the cellular 
level, bmp10 mutant hearts may have CM hypertrophy and increased proliferating cell nuclear 
antigen (PNCA) signal. Our long-term goal is to use this zebrafish model to understand the 
mechanisms involved in cardiac compensation and in the pathological progression to heart failure, 
which may aid in design of medical therapies to prevent HOHF in HHT patients. Also, in addition 
 v 
to HHT, HOHF is identified in some common diseases, such as morbid obesity, anemia and sepsis, 
and HOHF is associated with high mortality. Hence, studying this type of heart failure is of public 
health significance.  
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1.0 Background and Significance 
1.1 Introduction to Heart Failure 
Heart failure is a global public health problem, laying a substantial burden on society, 
family and the individual. Heart failure affects at least 26 million people worldwide, and its 
prevalence keeps increasing as the population ages. Mortality and morbidity are high, and 
expenditure is vast due to the high hospitalization rate and related health care cost (Savarese & 
Lund, 2017). Clinical and basic research in cardiology have been growing vigorously in attempt 
to develop therapeutics that can prevent or slow down the heart failure process. This goal drives 
us to better classify the types of heart failure, study their etiology, and conduct mechanistic analysis 
of disease progression. Based on the clinical descriptions of cardiac output, heart failure can be 
classified as low output heart failure (LOHF) or high output heart failure (HOHF).  
LOHF is common and is further subtyped as systolic heart failure and diastolic heart 
failure. The underlying mechanism in systolic heart failure is the heart not being able to pump 
adequately. The left ventricular muscle weakens, and the left ventricle is not pumping with enough 
force to allow normal circulation. Systolic heart failure may be caused by high blood pressure, 
coronary artery disease, or myocardial infarction. Systolic heart failure is also clinically called 
heart failure with reduced ejection fraction, in which there is an increase in end systolic volume 
while also a greater increase in end diastolic volume. The left ventricle shape changes from 
ellipsoidal to globular (Chatterjee, 2012). Also, the left ventricle cavity increases while its wall 
thickness may be unchanged or decreased. These two findings are associated with an increase in 
wall stress (Chatterjee, 2012). The increased wall stress together with the impaired contractility 
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causes the reduced ejection fraction. Left ventricular dilation may progressively worsen in patients 
without adequate pharmacotherapy treatment and may lead to more severe heart failure. In systolic 
heart failure, abnormal collagen deposition is also observed in the left ventricle tissue (Rossi et al., 
2004). 
In diastolic heart failure, left ventricular muscle stiffens and increases resistance against 
filling. Diastolic heart failure is caused by high blood pressure, aging, diabetes, and other causes. 
In clinic, a normal ejection fraction is observed in diastolic heart failure, thus it is also called heart 
failure with preserved ejection fraction. The preserved ejection fraction is attributed to decreased 
end-systolic and end-diastolic volumes. Diastolic heart failure is characterized by increased left 
ventricular wall stiffness and/or thickness, and increased cardiomyocyte (CM) size (Aurigemma, 
Zile, & Gaasch, 2006). There is also an increase in collagen bundle thickness, but the collagen 
volume remains normal (Aurigemma, Zile, & Gaasch, 2006).  
HOHF is rare. It is a condition in which the heart, in an effort to generate high cardiac 
output to maintain blood pressure, exceeds its pumping capacity and progresses to heart failure. In 
healthy people, high cardiac output temporarily occurs during exercise, in order to meet the 
increased demand for oxygen and energy. In some disease conditions, high cardiac output persists 
and eventually leads to heart failure. The underlying disease states include chronic anemia, chronic 
hypercapnia, sepsis, and systemic arterio-venous fistula. Except for cardiomegaly, there is little 
known about the structural change in HOHF. However, the underlying pathophysiology is clear. 
Vasodilation or arteriovenous shunts lead to reduced systemic vascular resistance and thus a fall 
in arterial blood pressure (Mehta & Dubrey, 2009). Low arterial blood pressure results in neural 
hormonal activation, which includes activation of the sympathetic nervous system and the renin-
angiotensin-aldosterone system (RAAS). In this response, sympathetic activation leads to 
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increased heart rate and increased vasoconstriction, and over time, ventricular remodeling, which  
increases stroke volume which in turn increases arterial blood pressure. RAAS activation results 
in water and salt retention, and thus the expansion of the blood volume, another strategy to increase 
arterial blood pressure. Despite the increased heart rate and increased stroke volume, the ejection 
fraction may be unchanged because of the proportional increases in end-systolic volume and end-
diastolic volume. Compensatory left ventricular dilation and/or hypertrophy may progress to heart 
failure.  
1.2 HOHF Pathogenesis: HHT and AVMs 
HHT has a broad spectrum of manifestations and highly variable expressivity. Although 
the primary defect is the presence of AVMs, they can form at multiple sites affecting different 
organs, and the dilation or rupture of the vessels can lead to secondary and tertiary consequences 
(Shovlin, 2015). Liver AVMs are associated with one of the most severe secondary consequences, 
HOHF. Patients with liver involvement can have a cardiac index (CI, cardiac output/body surface 
area,) > 3.9 L/min/m2 (Anand & Florea, 2001), while the normal range for CI is 2.5-4 L/min/m2 .  
In HHT, liver involvement manifests as disseminated intrahepatic telangiectasias and 
shunting from the hepatic artery to the hepatic veins (Garcia-Tsao, 2007). The reduced systemic 
vascular resistance causes a fall in arterial blood pressure, which leads to the activation of the 
neural hormonal system. Moreover, the organs in which AVMs form suffer tissue hypoxia and 
insufficient metabolism due to lack of oxygen and nutrition exchange through capillary bed, 
another factor that stimulates neural hormonal changes. Also, AVMs at other sites, such as the 
nose and GI tract, are easily ruptured by the high blood flow, resulting in hemorrhages, anemia, 
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and a further reduced arterial oxygen content. All these physiological factors contribute to 
increased stroke volume (Shovlin, 2015). To date, the only proven therapy for HOHF is liver 
transplantation. Conventional therapies for low-output heart failure are ineffective because they 
have vasodilatory properties, which will further decrease the vascular resistance (Mehta & Dubrey, 
2009). Therapeutic strategies for treating HOHF include preventing formation of AVMs or 
preventing heart failure progression. This calls for a deeper mechanistic understanding of HHT 
and HOHF. 
1.3 HHT Genetics 
Mutations in ENG, ACVRL1, and SMAD4 are responsible for HHT (McAllister et al., 1994; 
Johnson, et al., 1996; Gallione, et al., 2004). They encode BMP signaling pathway components 
that act in endothelial cells (ECs) lining blood vessel. In normal signal transduction  (Roman & 
Hinck, 2017), circulating BMP ligands bind to the type I receptor serine/threonine kinase, 
ACVRL1 (also called ALK1), in concert with typeⅡ receptor serine/threonine kinases, BMPRII, 
activin receptor A or activin receptor B. Ligand binding is aided by the non-signaling type Ⅲ 
receptor, endoglin (ENG). The typeⅡ receptors phosphorylate the typeⅠreceptor, ALK1, which 
then phosphorylates SMAD1, SMAD5, or SMAD8 in the cytoplasm. Phosphorylated SMAD1/5/8 
proteins recruit the common partner SMAD4 and enter the nucleus and regulate gene expression. 
In HHT, patients are heterozygous for one of the three genes, indicative of haploinsufficiency. 
Therefore, one therapeutic strategy for HHT is to enhance BMP signaling in endothelial cells via 
increasing circulating BMP ligand to activate the remaining functioning receptor. BMP9 and 
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BMP10 are two known ligands with high affinity to ALK1 receptor (Brown et al., 2005; David et 
at., 2007), but evidence suggests they might have functional redundancy (Chen et al., 2013). To 
identify the physiological ligand(s), our lab generated zebrafish mutant lines bmp9, bmp10, and 
bmp10-like (a paralog to bmp10 in zebrafish). In our ligand requirement study, we found a unique 
and surprising requirement for zebrafish bmp10: bmp10 mutants develop an adult phenotype 
highly similar to HHT patients, including skin, liver and heart involvement.  
1.4 Zebrafish Model for HHT: alk1 and bmp10 mutants 
1.4.1  alk1 mutants as an HHT model  
Using zebrafish alk1 mutants as an HHT model, we have gained insight into how disruption 
of alk1 leads to AVMs. Our alk1 mutant line was isolated in a forward genetic screen (Driever et 
al., 1996). alk1 mutants nicely phenocopy HHT vasculature, exhibiting AVMs in cranial vessels 
at 2 days post-fertilization with complete penetrance (Roman et al., 2002). In a previous study 
(Rochon, Menon, & Roman, 2016), we showed that loss of alk1 alters EC migration in the arteries 
proximal to heart. In wild type embryos, ECs in cranial arteries migrate against blood flow, while 
in alk1 mutants, the EC migration against flow is weakened and EC migration in the direction of 
blood flow is enhanced. This phenomenon results in increased EC number in and caliber of distal 
arterial segments. AVMs then form downstream of enlarged, Alk1-positive vessels in the presence 
of blood flow: at least one normally transient arterial-venous blood vessel segment is aberrantly 
retained (Corti et al., 2011), likely in response to increased shear stress.  
 
 6 
Alk1 ligands in zebrafish 
As introduced above, zebrafish have three Alk1 ligands: Bmp9, Bmp10 and Bmp10-like. 
Bmp10 and Bmp10-like are likely duplicates that arose as  a result of  a whole-genome duplication 
event in teleost (Woods et al., 2005). At the protein level, the growth factor domain of Bmp10-like 
is 63.3% identical to Bmp10. To investigate Alk1 ligand requirements, our lab generated bmp9, 
bmp10, and bmp10-like mutants: no single mutant shows abnormal vessel formation, confirming 
our previously published knockdown results (Laux et al., 2013). However, combined loss of 
bmp10 and bmp10-like phenocopies alk1 mutants, suggesting that both genes encode Alk1 ligands 
with functional redundancy (T. Capasso and B. Roman, unpublished).  
Despite the fact that bmp10 and bmp10-like paralogs are redundant with respect to 
embryonic vascular development, expression patterns suggest the possibility of 
subfunctionalization: bmp10 is expressed in endocardium and bmp10-like in myocardium at 36 
hours post-fertilization (Laux et al., 2013). Observation of these mutants throughout life bears out 
this prediction:  bmp10 mutants develop a distinct cardiovascular phenotype during the juvenile to 
adult period.  
1.4.2  Identification of adult phenotype in bmp10 mutants  
1.4.2.1 bmp10 mutant phenotype 
Zebrafish bmp10 mutants show dilated skin vessels and/or abdominal edema as early as 6 
weeks. Phenotype onset spans a wide range of age and presents with variable expressivity. Before 
3 months, the most frequently seen external phenotype is abdominal edema with sparse skin 
hemorrhages; internally, these fish have ascites and pale liver and other organs. In a minority of 
phenotypic bmp10 mutants, edema resolved to some extent, while most of those with edema 
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became progressively worse and died before 3 months (B. Li, data not shown). At 5 months, some 
bmp10 mutants grew to a similar size as their wild type (WT) siblings, exhibiting dilated anterior 
vessels and hemorrhages (Fig. 1A). Other mutant fish were short and thin, while some appeared 
larger with edema, and others were indistinguishable from wild type siblings. In addition to eternal 
vascular lesions, at 5 months, some bmp10 mutants had a plexus-like vessel network and dilated 
arteries in the liver (Fig. 1B). At 12 months, most mutants only had slightly dilated vasculature in 




Figure 1. bmp10 mutant vessel and heart phenotype at 5 months.  
(A) In comparison with the normal appearance of the WT sibling, bmp10 mutant shows dilated vessels and 
hemorrhages in the anterior. Scale bars: 1 mm. Normal heart and enlarged and abnormally shaped heart from the 
fish in the left. Scale bars: 200 µm. a, atrium; v, ventricle; b, bulbus arteriosus. 
(B) Liver vessel images show bmp10 mutant has dilated arteries (arrow) and plexus-like network (arrowhead). 
Arteries are in magenta and veins in green. Scale bars: 100 µm. N = 3 (WT) and 6 (bmp10 mutant); 1 experiment. 
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1.4.2.2 Correlation of vessel and heart phenotypes in bmp10 mutant 
At all time points, when the heart is dissected from externally phenotypic bmp10 mutants, 
an irregular ventricular shape with or without enlargement is consistently seen, while non-
phenotypic bmp10 mutant hearts seem normal. A close correlation between the severity of vessel 
defects and heart abnormality is observed. This leads us to hypothesize that the bmp10 mutant 
heart is adapting to the altered volume and pressure of blood flowing through the abnormal 
vascular structure, mimicking the HOHF phenotype in human patients.  
1.4.3  Zebrafish as a model for cardiac disorders 
Zebrafish can serve as a valuable in vivo model for investigating acquired or heritable 
cardiac disorders. Cardiac remodeling in response to hemodynamic changes has been 
demonstrated in an anemia-induced HOHF model (Sun et al., 2009). Also, adult fish have been 
used to study the progression of cardiac disease caused by environmental assault. For example, 
adult zebrafish show consistent heart failure by chronic isoproterenol activation on β-adrenergic 
receptor (β-AR), displaying similar changes on functional and molecular levels to mammals 
(Kossack et al., 2017). What is more, based on embryonic studies, zebrafish mutants show heart 
phenotypes involving the contractile machinery and rhythmicity, which resemble the 
characteristics of human cardiac disease (Nguyen, Lu, Wang, & Chen, 2008). These observations 
support the notion that the mechanisms regulating these processes are conserved from fish to 
mammal. Developmentally, the zebrafish heart and the mammalian heart undergo similar 
morphogenetic processes  (Nguyen, Lu, Wang, & Chen, 2008). After heart tube formation and 
looping, both fish and mammals develop cardiac ridges protruding from the ventricle wall, a 
process called trabeculation (Sedmera & Thomas, 1996). Fish hearts remain trabeculated 
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throughout life while mammalian hearts get compacted at a later stage of development (Burggren 
et al., 1991). Another difference between fish and mammalian hearts is that the fish heart only has 
two chambers, atrium and ventricle, with no septum dividing the chambers (Burggren et al., 1991). 
One other unique characteristic of the zebrafish heart is its ability to regenerate throughout life. 
Zebrafish CMs are capable of proliferating and repairing cardiac injury without leaving a scar 
(review by González-Rosa et al., 2017). Despite these differences, the zebrafish heart is a valuable 
model of human heart disease. 
1.5 BMP10’s Documented Role in Cardiovascular System 
BMP10 has dual roles in vessel and heart development in mouse (Chen et al., 2004; Chen 
et al., 2013). Bmp10 knockout mice show embryonic fusion of artery and vein, and abnormal 
vasculature in yolk sac, suggesting its crucial role in embryonic vascular development (Chen et 
al., 2013). BMP10 also regulates the outgrowth of myocardium in both embryonic and postnatal 
heart in mouse (Chen et al., 2004; Chen et al., 2006). Whole-mount in situ hybridization on mouse 
embryos shows Bmp10 is exclusively expressed in embryonic heart. Its expression is first confined 
to developing ventricular trabeculae at E9.0 and then shifts to the atrial wall at E13.5 (Neuhaus, 
Rosen, & Thies, 1999). Knockout experiment provides further evidence to support BMP10’s role 
in trabeculae outgrowth (Chen et al., 2004). Bmp10-deficient hearts fail to develop ventricular 
trabeculae at E9.5 and show acellular endocardial cushions. Overexpression provides another 
approach to assess BMP10’s role in postnatal myocardium (Chen et al., 2006). Bmp10 expression, 
driven by an α-myosin heavy chain (α-MHC) promoter that is activated specifically in postnatal 
myocardium, results in a significantly smaller heart, and this defect is solely due to inhibited 
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normal cardiomyocyte hypertrophy, while the cardiomyocyte number is not different compared to 
WT siblings. 
It is known that BMP10 can bind to ALK1, but the BMP10 receptors in the heart remain 
unclear. BMP10 has a high affinity for ALK1, and it has been shown that ALK1 can transduce 
BMP10 signaling in the endothelial cells (Castonguay et al., 2011). As for the heart, Alk3 and Alk6 
are both expressed in the murine postnatal heart, but Alk1 is not. Both ALK3 and ALK6 can 
transduce BMP10 signaling in MC3T3 cells (Mazerbourg et al., 2005). It is believed that ALK3 is 
a stronger candidate for BMP10 cardiac receptor than ALK6, as ALK3 expression is 1000-fold 
higher than ALK6 in postnatal mouse hearts (Mazerbourg et al., 2005). It has also been shown that 
Alk3 is required for the normal development of trabeculated myocardium, compact myocardium, 
and endocardial cushions in mouse (Gaussin et al., 2002), while ALK6 is associated with a BMP2-
mediated atrioventricular canal endocardium transformation in chick (Okagawa, Markwald, & 
Sugi, 2007).  
1.6 HOHF and Public Health 
The causes of HOHF are collectively common, including anemia, sepsis, obesity, liver 
disease, vasodilation and AVMs (Reddy  et al., 2016). HOHF is secondary to these conditions, and 
its prevalence is highly related to them. However, HOHF may not be detected at early stages or 
properly diagnosed. Patients with conditions that can cause HOHF may have high cardiac output 
but no symptoms of clinical heart failure (Reddy et al., 2016); nevertheless, this state could 
progress to decompensation and become life-threatening. What is more, HOHF exhibits preserved 
ejection fraction, and if cardiac output is not assessed in patients, they may be misdiagnosed with 
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low output systolic heart failure, leading to inappropriate treatment (Reddy et al., 2016). Currently 
there is no proven therapy directly treating HOHF, and it can only be alleviated by correcting the 
underlying etiology: in the case of HHT, this means liver transplantation. Therefore, it is necessary 
to include the diagnostic evaluation and continued monitoring of HOHF when treating patients for 
conditions associated with this underrecognized disease. From the public health perspective, 
increasing awareness of HOHF is needed.  
1.7 Significance 
If we validate zebrafish bmp10 mutants as a model for HOHF, it will enable us to gain 
valuable insight into the course of heart failure progression. It is unclear on the cellular and 
molecular level the changes that occur during the compensatory to decompensatory transition 
phase of HOHF. Once we understand the mechanism underlying the progression, we could target 
some dysregulated molecular pathway and develop therapeutics. Furthermore, if we characterize 
the molecular changes in HOHF with zebrafish bmp10 mutants, we may find specific biomarkers 
to aid diagnosis.  
1.8 Objectives 
Zebrafish bmp10 mutants provide a unique opportunity to analyze the effect of dilated 
vessels on the normally developed heart, thanks to the subfunctionalization of bmp10 paralogs. In 
this study, my goal was to determine whether the cardiac phenotype in bmp10 mutants represents 
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HOHF. This is important as we clarify the etiology of the abnormal heart. We reason that if our 
data show high cardiac output, it strongly suggests the heart is adapting to the dilated vasculature. 
To address this question, we performed echocardiography on adult zebrafish, allowing us to assess 
heart function and compare the zebrafish findings with those of human HOHF. 
Specific Aim 1: Determine whether bmp10 mutant hearts exhibit a high output state. 
Hypothesis: To adapt to the reduced vascular resistance, the bmp10 mutant heart generates 
a high cardiac output.  
Method: In collaboration with Dr. Kang Kim in the Department of Medicine and 
Bioengineering, we used a high-resolution small animal ultrasound imaging scanner (Vevo2100, 
Fujifilm Visual Sonics) to measure stroke volume and cardiac output.  
Specific Aim 2: Use bmp10 mutant as a model to understand the pathophysiology of 
HOHF.  
2a. Characterize the morphological features of the bmp10 mutant heart. 
Hypothesis: If bmp10 mutant has high cardiac output, the heart may change its muscle 
layers’ morphology to increase the pumping capacity. 
Method: To gain a whole picture of the bmp10 mutant heart, I used histochemistry to 
analyze histology and transmission electron microscopy (TEM) to assess cellular ultrastructure.  
2b. Study the cellular changes in the progression of HOHF   
The cardiac remodeling process in HOHF is largely unknown. Probing the cellular 
progression may help us understand the pathophysiology and lay a foundation for developing a 
specific therapy. 
Method: I assessed CM proliferation, shape, size, sarcomere organization, and nucleus 
number in bmp10 mutant heart.  
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2.0  Material and Methods 
2.1 Fish Husbandry and Fish Size Standardization 
Zebrafish were maintained according to standard protocol and used in experiments 
approved by Institutional Animal Care and Use Committee of University of Pittsburgh.  
As zebrafish growth rate is largely affected by the stocking density, we maintained the tank 
density as larvae grew for both bmp10 mutant and the WT siblings. After embryos were handled 
using standard methods, larvae from 5 days to 6 weeks post-fertilization were moved to system 
and grown at 40 fish/2.8 liter tank, and juveniles after 6 weeks were maintained at 20 fish/2.8 liter 
tank, by supplementing with age-matched Glofish.  
bmp10pt527 allele in zebrafish was genotyped as follows. PCR primers used were Forward: 
CAAAGTAGCCCCATCAGCTC; Reverse: CTTCAGGGTCTCCATCAAGC. 
PCR products were digested with BstNI restriction enzyme in NEB2.1 buffer (New England 
Biolabs) and run on 3% Metaphor gel (Lonza). bmp10 mutants would show one band at 138 bp, 
while WT siblings two bands at 94 bp and 44 bp.  
2.2 Zebrafish Echocardiography  
Experiment setting 
Zebrafish echocardiography was  performed as described in a previous study (Wang et al., 
2017), with minor modifications. We used a lower dose of tricaine than previously suggested to 
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induce and maintain anesthesia in both bmp10 mutant and WT siblings, as bmp10 mutants are 
overly sensitive to anesthesia. We induced anesthesia by putting zebrafish in 0.45 mmol/L tricaine-
system water for 2 minutes, maintained the fish in 0.36 mmol/L tricaine for 2 minutes, and 
performed the scan in the same solution. It took 5 minutes to scan each fish. We performed 
echocardiography using a Vevo 2100 imaging system (FujiFilm VisualSonics, Toronto, Canada) 
equipped with a high frequency linear array transducer (MS 700, with bandwidth 30-70 MHz, 
centered operating frequency at 50 MHz). 
Image analysis 
We derived cardiac measurements from the ultrasound images with Vevo LAB software 
(FujiFilm VisualSonics) using the previously published procedure for heart rate, ventricular 
outflow velocity, end-systolic, and end-diastolic diameter in longitudinal view. Fractional 
shortening is calculated as FS = (end-diastolic diameter - end-systolic diameter)/end-diastolic 
diameter (Wang et al., 2017). As for stroke volume, we reasoned that as the zebrafish ventricle is 
highly trabeculated, it is more accurate to measure it by pulsed waveform Doppler. It is based on 
measurement of the ventricular outflow tract area and the range of velocities of blood flow across 
that area, also known as velocity time integral: stroke volume = ventricular outflow tract area × 
velocity time integral. To standardize stroke volume, we indexed stroke volume to the fish body 
weight. 
2.3 Transmission Electron Microscopy 
Zebrafish hearts were dissected and briefly rinsed in Ringer’s solution. They were then 
fixed in cold 2.5% glutaraldehyde in 0.01 M PBS for at least one hour. The hearts were rinsed in 
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PBS, post-fixed in 1% osmium tetroxide with 1% potassium ferricyanide, rinsed in PBS, 
dehydrated through a graded series of ethanol and propylene oxide and embedded in Poly/Bed® 
812 (Luft formulations). Semi-thin (300 nm) sections were cut on a Leica Reichart Ultracut, 
stained with 0.5% Toluidine Blue in 1% sodium borate and examined under the light microscope. 
Ultrathin sections (65 nm) were stained with uranyl acetate and Reynold’s lead citrate and 
examined on JEOL 1011 transmission electron microscope (grant # 1S10RR019003-01 NIH for 
Simon Watkins) with a side mount AMT 2k digital camera (Advanced Microscopy Techniques, 
Danvers, MA). 
2.4 Extracellular Matrix Component Staining  
Zebrafish hearts were fixed in Bouin’s solution at 4°C overnight and processed through 
standard paraffin embedding procedure. 5 µm sections were cut on a microtome and mounted on 
positively charged glass slides (Shandon™ ColorFrost™ Plus Slides).  
Before subjected to ECM component staining, sections were deparaffinized by toluene and 
rehydrated through a graded series of ethanol and PBS. Consecutive sections were used for Acid 
Fuchsin Orange G (AFOG), Hart’s elastin, and Movat’s pentachrome stain using standard staining 
protocols. 
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2.5 Cardiomyocyte Size Measurement 
Transgenic fish Tg(myl7:actn3b-EGFP)sd10; Tg(myl7:MKATE-CAAX)sd11 were used in this 
experiment to analyze sarcomere structure and cell size. CMs were isolated according to the 
previous study (Sander, Sune, Jopling, Morera, & Izpisua Belmonte, 2013). Briefly, for each 
sample, the explanted ventricle was washed in heparin buffer (1× PBS plus 10 U/ml heparin and 
100 U/ml penicillin-streptomycin), and then incubated in 250 µl digestion buffer (1× PBS plus 10 
mM HEPES, 30 mM taurine, 5.5 mM glucose, 10 mM BDM, 12.5 µM CaCl2, and collagenases II 
and IV (5 mg/ml each)) for 2 hours at 32°C in a 2 ml screw-cap tube. During incubation, the tubes 
were gently flipped every 10 minutes, and after incubation the mixture was gently pipetted up and 
down to completely dissociate the tissue. Then the homogeneous cell suspension was mixed with 
an equivalent volume of 4% paraformaldehyde (PFA), placed at room temperature for 10 minutes, 
and centrifuged at 250 × g for 5 minutes at room temperature. The supernatant was carefully 
removed and 250 µl DAPI (0.1 µg/ml) in Stop Buffer (1× PBS plus 10 mM HEPES, 30 mM 
taurine, 5.5 mM glucose, 10 mM BDM, and 12.5 µM CaCl2) was added to the pellet and incubated 
for 10 minutes at room temperature. The samples were centrifuged again at 250 × g for 5 minutes 
at room temperature. The supernatant was carefully taken off and the pellet was resuspended in 30 
µl of VECTASHIELD® Antifade Mounting Media (H-1000, Vector Laboratories) by gentle 
pipetting. The entire CM suspension was pipetted onto the slide and covered with cover glass. 
Slides were imaged using Nikon A1 outfitted with CFI Apochromat LWD 20× water immersion 
objective. CM areas were measured by ImageJ.  
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2.6 Immunofluorescence Staining  
For localizing the PCNA signal, we used transgenic fish Tg(fli1:nEGFP)y7;Tg(-
5.1myl7:nDsRed2)f2, which have endocardial/endothelial and myocardial nuclei highlighted with 
green and red fluorescence, respectively. Zebrafish heart explants were fixed in freshly-made 4% 
PFA at room temperature for 2 hours, then washed in PBS and immersed in 30% sucrose at 4°C 
for cryoprotection. Hearts were then embedded in cryomedium (Tissue-Tek® O.C.T. Compound, 
Sakura® Finetek, SAKURA FINETEK USA INC) and stored at -80°C. 14 µm frozen sections 
were cut on a cryotostat (Thermo Scientific FSE) and stored at -80°C for up to several months. For 
immunofluorescence staining, slides were retrieved and placed at room temperature for 30 
minutes. Slides were then washed in PBS and incubated in mixture of 30% H2O2 :100% Methanol 
(1:9) for 45 minutes, washed in PBST (1×PBS plus 0.1% Tween-20) and incubated in blocking 
solution (5% goat serum in PBDT (PBS/ 0.1% tritonX-100/ 0.1% DMSO) for 1 hour at room 
temperature in a humidified box. PCNA antibody (P8825; Sigma, St. Louis, MO, USA) was 
diluted to 1:1500 with blocking solution and applied to the slides. Slides were incubated at 4°C in 
humidified box overnight. Slides were washed in PBST at 4°C on rocking platform in the dark, 
and then incubated in DAPI (0.1 µg/ml) plus goat anti-mouse Alexa Fluor 647 (1:200; A21235; 
Invitrogen) in blocking solution and at 4°C overnight. Slides were washed in PBST and mounted 
with VECTASHIELD® Antifade Mounting Media (H-1000, Vector Laboratories). Confocal 
images were acquired with a Nikon A1 outfitted with CFI Apochromat LWD 20x water immersion 
objective. Z series were obtained in 2 µm steps and spectral imaging with linear unmixing 
technique was used to eliminate autofluorescence according to manufacturer’s instructions.  
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2.7 Statistics 
Cardiac function and CM size data were statistically analyzed by two-tailed unpaired 
student t-test with significance set at p < 0.05. Graphs of data were generated by Prism7 




3.1 Cardiac Functional Changes in bmp10 mutants 
bmp10 mutants have supra-normal cardiac outputs, which exceed the pumping capacity of the 
heart.  
 We hypothesized that due to the dilated hemorrhagic vessels and the resultant anemia, the 
bmp10 mutant may have a high cardiac output state. To test this hypothesis, we 
performed echocardiographic studies in phenotypic bmp10 mutants and WT siblings at 3, 5, 
and 12 months (mixture of males and females). As the zebrafish heart is highly trabeculated, 
instead of using a method developed for compacted mammalian heart, we calculated stroke 
volume by multiplying the ventricular outflow tract (VOT) area and the velocity time integral 
of blood flow across the VOT. Also, considering the fish body size may be a confounding factor, 
we normalized the volume data to the total body weight. At all timepoints, bmp10 mutants 
exhibited a trend toward elevated stroke volume compared to WT sib, with significant 
increases at 3 and 12 months but not at 5 months (Fig. 2A). However, when normalized to 
body weight, stroke volume was significantly increased in bmp10 mutants at all time points 
(Fig. 2B). The effect on stroke volume was particularly striking at 3 months, suggesting 
that earlier onset phenotype is associated with increased severity of heart dysfunction. 
Cardiac output in bmp10 mutants is significantly higher at 3 and 5 months but not at 12 months, 
if total body weight is taken into account (Fig. 2C, D). Slow heart rates were also detected in 
bmp10 mutants at 3 and 5 months. All data regarding cardiac output are summarized in 
Tables 1-3. Fractional shortening remains unchanged at all the time points (see Supplemental 
Tables 1-3). Taken together, the results suggest that volume overload due to decreased
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vascular resistance leads to cardiac enlargement and a high output state. As such, these data 
suggest that this bmp10 mutant is a good model for HOHF associated with HHT.  
Figure 2. Stroke volume and cardiac output of bmp10 mutants. 
Echocardiography was performed in bmp10 mutants with phenotype and the WT siblings at 3, 5 and 12 months. (A) 
Stroke volume in bmp10 mutants was elevated at 3 and 12 months, but not at 5 months.  
(B) Higher stroke volume in bmp10 mutants at all time points, when data were indexed to total body weight.
(C) Cardiac output (stroke volume × heart rate) is not significantly different between groups.
(D) A high cardiac output state was observed in bmp10 mutant at 3 and 5 months in indexed data. Data are mean ±
s.d.; two tailed unpaired t-test, *p < 0.05, **p < 0.01. 3 months: N = 21 (WT, 16 males, 5 females) & 28 (bmp10
mutant, 25 males, 3 females). 5 months: N = 13 (WT, 11 males, 2 females) and 16 (bmp10 mutant, 13 males, 3
females). 12 months: N = 6 (WT, all males) and 8 (bmp10 mutant, all males). Experimental repeats: 3 (3 months); 2
(5 months); 1 (12 months).
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Total body weight (g) 0.13±0.05 0.09±0.07 0.04 
Heart rate (bpm) 180.89±25.54 140.93± 38.34 <0.001b 
Ventricular Outflow tract diameter (mm) 0.24±0.03 0.24±0.04 0.99 
Velocity time integral (mm) 6.21±2.13 9.28±5.72 0.013 
Stroke volume (mm3) 0.27±0.08 0.43±0.29 0.011 
SV / weight (mm3 g-1) 2.28±0.83 5.40±3.08 0.001a 
Cardiac output (mm3 min-1) 49.95±16.86 59.58±40.06 0.25 
Cardiac output / weight (mm3min-1 g-1) 410.98±155.13 764.85±576.65 0.004a 






Total body weight (g) 0.12±0.04 0.08±0.06 0.03 
Heart rate (bpm) 180.10±25.35 132.95±31.68 <0.001b 
Ventricular Outflow tract diameter (mm) 0.25±0.03 0.25±0.04 0.61 
Velocity time integral (mm) 5.60±1.72 7.14±3.92 0.14 
Stroke volume (mm3) 0.27±0.09 0.40±0.29 0.088 
SV / weight (mm3 g-1) 2.28±0.83 5.23±3.50 0.0025a 
Cardiac output (mm3 min-1) 48.19±18.18 51.11±36.98 0.76 
Cardiac output / weight (mm3 min-1 g-1) 412.54±163.27 698.07±515.41 0.037a 






Total body weight (g) 0.45±0.07 0.48±0.16 0.67 
Heart rate (bpm) 152.61±27.58 144.96±25.42 0.60a 
Ventricular Outflow tract diameter (mm) 0.28±0.03 0.29±0.02 0.51 
Velocity time integral (mm) 7.77±2.14 13.66±5.62 0.02 
Stroke volume (mm3) 0.49±0.18 0.91±0.36 0.03 
SV / weight (mm3 g-1) 1.10±0.35 2.00±0.95 0.04a 
Cardiac output (mm3 min-1) 78.70±43.54 133.18±59.55 0.08 
Cardiac output / weight (mm3 min-1 g-1) 175.35±93.90 295.16±157.45 0.13 
* Unpaired t-test used to compare means between groups
Parameter values given as mean ± s.d.
a. agree with the HOHF clinical findings
b. do not agree with the HOHF clinical findings
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3.2 Morphological Changes in bmp10 mutants 
bmp10 mutant early-onset vascular phenotype is associated with CM disorganization. 
In our ultrasound study, hyperdynamic circulation and an enlarged, rounded ventricle are 
observed in bmp10 mutants, with earlier onset phenotype being more severe than later onset 
phenotype. I hypothesized that the shape change in the bmp10 mutant heart represents a structural 
adaptation that allows for a higher cardiac stroke volume. Therefore, I analyzed the ultrastructure 
of the ventricle in phenotypic bmp10 mutant hearts compared to their WT siblings. I found that 
the structural changes in bmp10 mutant hearts do not represent a progressive phenotype, and that 
earlier age of onset correlates with worse outcome. 
Before 6 weeks, the zebrafish ventricle is comprised of a single-cell thick primordial layer 
and trabeculated myocardium, while after 6 weeks, an additional layer called the cortical layer 
covers the ventricle wall (Gupta & Poss, 2012) (Fig. 3). At 3 months, the outermost muscle layer 
of the ventricle wall of the phenotypic bmp10 mutant was the primordial layer (11/11), whereas a 
minority of the wild-type siblings presented with a newly-developed cortical layer enveloping the 
heart (2/8) (Fig. 4A). In the trabeculated layer, the bmp10 mutant hearts showed loosely compacted 
muscle, with larger spaces between the CMs (10/11) (Fig. 4A).  
At 5 months, bmp10 mutants’ cortical layer was formed (3/3) (Fig. 4B), showing that loss 
of bmp10 does not impair the ventricle’s ability to develop a cortical layer. The role of the cortical 
layer is to strengthen the ventricle wall in response to the increased circulation demand as the fish 
grows (Gupta & Poss, 2012). With the cortical layer present, bmp10 mutants’ trabeculated layer is 
mildly affected, showing only small gaps between CMs (3/3) (Fig. 4B).  
At 12 months, bmp10 mutants have a relatively thick cortical layer (Fig. 4C) in 4/11 
(36.4%), while WT siblings had a similar phenotype in 2/9 (22%). Only a mild change occurs in 
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the trabeculated layers of the bmp10 mutant heart, with enlarged space between CMs (9/11) (Fig. 
4C). Overall, my data suggest that the bmp10 mutant heart has loosely organized CMs.  
Figure 3. Juvenile zebrafish heart development. 
(A) The 30 days ventricle has two muscle layers, trabeculated myocardium and primordial layer of single CM
thickness.
(B) After juvenile organ maturation, ventricle is enveloped by an additional layer called cortical layer.
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Figure 4. Structural changes in bmp10 mutant heart. 
Toluidine blue stained semi-thin epon sections and ultrathin TEM sections at 3 months (A), 5 months (B), and 12 
months (C). Scale bars: 100 µm (toluidine blue); 10 µm (TEM). 
(A) At 3 months, bmp10 mutant has loosely arranged CMs in trabeculae. Arrows show laterally separated CMs;
arrowhead indicates loosely connected CMs. In bmp10 mutants, the ventricle wall is comprised of primordial layer
of single CM thickness; while in the WT sibling, the ventricle is enveloped by cortical layer. Blue dotted lines,
boundary of trabeculated layer; pink area, ventricle cavity. Tolidine blue: N = 8 (WT) and 11 (bmp10 mutant); 2
experiments. TEM, N = 3 (WT) and 3 (bmp10 mutant); 1 experiment.
(B) At 5 months, wider space is seen between trabeculae and CMs in bmp10 mutant. Cortical layer is developed in
both groups. Toluidine blue & TEM: N  = 3 (WT) and 3 (bmp10 mutant); 1 experiment for each.
(C) At 12 months, cortical layer muscle is mildly affected in bmp10 mutant, with gaps between CMs. Toluidine blue:
N = 9 (WT) and 11 (bmp10 mutant); 2 experiments. TEM: N = 3 (WT) and 3 (bmp10 mutant), 1 experiment.
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3.3 Extracellular Matrix Deposition in bmp10 mutant 
Extracellular matrix changes are not apparent in bmp10 mutant hearts. 
Because I detected large gaps between CMs in bmp10 mutants, I hypothesized that 
the gaps were filled with extracellular matrix. However, histological staining revealed no 
changes in collagen, elastin or proteoglycan deposition in bmp10 mutant hearts at 3 or 5 
months. (Supp. Fig. 1 and Fig. 5) 
Figure 5. Extracellular matrix component deposition in the WT sibling and bmp10 mutant heart at 5 months. 
No abnormal deposition of collagen, elastin or proteoglycan in the ventricle remodeling of bmp10 mutant at 5 
months.  
(A, B) Appearance of the WT sib and bmp10 mutant. Scale bars: 1 mm 
(C, D) Heart explants from fish in A and B. Scale bars: 200 µm 
(E, F) AFOG stained sections. Blue: collagen; red: fibrin; orange: muscle. Scale bars: 200 µm.  
(G, H) Hart’s Elastin stained sections. Purple: elastin; yellow: counterstain. Scale bars: 200 µm.  
(I, J) Movat’s stained sections. Black: nuclei, elastic fiber; yellow: collagen fiber, reticular fiber; blue: ground 
substance, mucin; bright red: fibrin; red: muscle. Scale bars: 200 µm.  
N = 3 (WT) and 3 (bmp10 mutant). 3 sections per heart. 1 experiment for each staining. 
3.4 Cardiomyocyte Hypertrophy in bmp10 mutant 
In bmp10 mutants, CM size is increased while CMs remain mononucleated and sarcomere 
structure is normal. 
An abnormally shaped heart with or without enlargement is seen in bmp10 mutants,
as well as altered cardiac function. I hypothesized that CM size is increased, and this 
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contributes to the functional and structural changes in bmp10 mutant heart. To analyze CM size 
and their sarcomere organization, I isolated CMs from adult zebrafish ventricle and analyzed the 
size with the aid of transgenes highlighting alpha-actinin (EGFP) and cell membrane (mKATE) in 
green and red, respectively. At 5 months, CMs of the bmp10 mutant heart tended to be larger than 
those of WT sibs, but this difference did not reach statistical significance. All of the CMs had a 
single nucleus, suggesting no endoreplication or dysregulation of cell cycle. Moreover, I detected 
no qualitative change in alpha-actinin organization in the sampled bmp10 mutant CMs (Fig. 6A). 
However, due to the experiment procedure, I suspect that impaired/dead CMs might have been 
removed with supernatant, and thus those with myofilament disorganization are not detected in the 
samples. Together, my data suggest bmp10 mutant may have CM hypertrophy to achieve increases 
in organ mass.  
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Figure 6. CM hypertrophy in bmp10 mutant at 5 months. 
(A) Representative images of CMs from WT and bmp10 mutant ventricles, 5 months. Green: Tg(myl7:actn3b-
EGFP)sd10 (Z-disc); magenta: Tg(myl7: mKATE-CAAX)sd11 (CM membrane); blue: DAPI (nucleus). Scale bar: 20
µm.
(B) CM area. WT: n = 3 hearts, 8-30 CMs/heart. bmp10 mutant:  n = 3 hearts, 90-155 CMs/heart. 1 experiment.
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3.5 Proliferation or DNA Damage in bmp10 mutant Heart 
bmp10 mutant hearts have elevated staining of PCNA in endocardial and myocardial cells. 
To dissect cellular changes in bmp10 mutant heart, I stained hearts for PNCA. At 3 months, 
PCNA signals were associated with edema in the mutants (6/6) (Fig. 7A, B, K, & L). Qualitative 
analysis of colocalization revealed enhanced proliferation in endocardial [Tg(fli1a: nEFGP)y7; 
5/6] and myocardial [Tg (cmlc2:nDsRed2)f2; 3/6] cells (Fig. 7C-H); the remaining mutant showed 
increased PCNA signal that failed to colocalize with either cell type. All analyzed fish 
showed edema, indicative of poor heart function (Fig. 7K, &L).  
Figure 7. Increased PCNA in bmp10 mutant heart at 3 months. 
(A, B) PNCA signal is largely increased in bmp10 mutant heart. Magenta: overall PCNA signal in heart. Scale bars: 
100 µm. 
(C, D) Sparse PCNA signals overlap with endocardial nuclei. Red: PCNA; blue: endocardial nuclei; white: 
overlapping signal; pseudocolored by colocalization analysis in ImageJ.  
(E, F) green: endocardial nuclei 
(G, H) PCNA signals overlap with myocardial nuclei. Red: PCNA; blue: myocardial nuclei; white: overlapping 
signal; pseudocolored by colocalization analysis in ImageJ.  
(I, J) orange: myocardial nuclei 
(K, L) bmp10 mutant with increased PCNA showed edema. Scale bars: 1 mm. N = 4 (WT) and 6 (bmp10 mutant) 
hearts, 3 sections per heart. 1 experiment. 
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4.0 Discussion 
The central finding of this study is that depletion of bmp10 leads to dilated and hemorrhagic 
vasculature and induces HOHF. We think the zebrafish bmp10 mutant may serve as a valuable 
model for HOHF.  
In this study, we detected increased stroke volume index and preserved fractional 
shortening at all the time points in bmp10 mutants. These results are consistent with the clinical 
findings in HOHF. In bmp10 mutants, the early onset of the vascular abnormality is correlated 
with a more severe outcome in terms of changes in stroke volume and the overall well-being of 
the fish, such as showing raised scales. This could be explained by the timing of cortical layer 
development, a maturation process of the ventricle in juvenile zebrafish that serves to strengthen 
the ventricle wall and to meet the increased hemodynamic need (Gupta & Poss, 2012). If bmp10 
mutants develop AVMs before the formation of the cortical layer, the ventricle wall of single CM 
thickness may not be able to compensate for the volume overload. Surprisingly, the vascular 
phenotype is also correlated with lower heart rate in bmp10 mutants. However, I suspect that the 
slow heart beat in bmp10 mutants may be due to the increased susceptibility of  bmp10 mutants to 
anesthesia. 
High cardiac output is generated by the heart with increased organ size and preserved 
systolic function in bmp10 mutants. The heart of phenotypic bmp10 mutants is large compared to 
body size. At the cellular level, preliminary data suggest that CMs are hypertrophic and the space 
between CMs is enlarged. I suspect that increasing CM volume and extracellular space reflects 
ventricular remodeling to increase organ mass. However, collagen is not deposited in the ventricle 
tissue, indicating no fibrosis. This is consistent with the fractional shortening data showing that 
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the bmp10 mutant heart has preserved contractility and systolic function. The echocardiography 
and collagen data in zebrafish bmp10 mutants agree with the clinical findings in HOHF, suggesting 
that the bmp10 mutant is a good model for HOHF. 
PCNA is detected in the ventricle of bmp10 mutants with edema. PNCA is a marker for 
proliferation while ubiquityl-PCNA is associated with DNA damage (Kanao et al., 2015). Our 
PCNA antibody detects both, so additional experiments will be necessary to differentiate these two 
possibilities. DNA damage may result from replication stress on DNA molecules or from 
mitochondrial dysfunction, as the bmp10 mutant heart is working harder, and mitochondria may 
not be able to make enough ATP, leading to reactive oxygen species (ROS) production and DNA 
damage. The PCNA signal is found in the at least two cell types, marked by a fli1a-driven 
transgene (endocardial or endothelial cells) or a myl7-driven transgene (CMs). Anti-PCNA signal 
in endocardial nuclei is sparse but detected in most samples. PCNA signal colocalizing with 
myocardial nuclei is present in half of the samples. Future work will be needed to determine 
whether enhanced PCNA expression is a protective or pathological response in the heart, and 
whether other gene expression changes are detectable in the bmp10 mutant heart, such as changes 
in CM contractility markers or sodium channels. 
Overall, these data show that the zebrafish bmp10 mutant is a useful HOHF model, and 
with this model we gain insights into the cardiac remodeling in HOHF. In our zebrafish model, 
HOHF is associated with increased heart size (Fig. 8A). At the tissue level, muscle fibers are 
separated, the extracellular space is increased, and multiple cells types are PCNA-positive, 
suggesting either proliferation or DNA damage (Fig. 8B). Further work is required to understand 
how these morphological changes lead to increased cardiac output in response to low systemic 
vascular resistance.  
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Figure 8. Model of cardiac remodeling in HOHF 
(A) Association of HOHF and increased heart size.
(B) Morphological elements and molecular change in HOHF
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Appendix A Supplemental Figure 
Supplemental Figure 1. Extracellular matrix component deposition in the WT sibling and bmp10 mutant heart 
at 3 months. 
No abnormal deposition of collagen, elastin or proteoglycan in the ventricle remodeling of bmp10 mutant at 3 
months.  
(A, B) Appearance of the WT sib and bmp10 mutant. Scale bars: 1 mm. 
(C, D) Heart explants from fish in A and B. Scale bars: 200 µm. 
(E, F) AFOG stained sections. Blue: collagen; red: fibrin; orange: muscle. Scale bars: 200 µm.  
(G, H) Hart’s Elastin stained sections. Purple: elastin; yellow: counterstain. Scale bars: 200 µm.  
(I, J) Movat’s stained sections. Black: nuclei, elastic fiber; yellow: collagen fiber, reticular fiber; blue: ground 
substance, mucin; bright red: fibrin; red: muscle. Scale bars: 200 µm.  
N=3 (WT) and 3(bmp10 mutant). 3 sections per heart. 1 experiment for each staining. 
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Appendix B Supplemental Tables 






End-systolic diameter (mm) 0.66±0.14 0.74±0.19 0.16 
End-diastolic diameter (mm) 0.84± 0.16 0.97±0.22 0.05 
Fractional shortening (%) 21.10±3.77 23.37±7.63 0.27a 






End-systolic diameter (mm) 0.85±0.09 0.86±0.14 0.84 
End-diastolic diameter (mm) 1.06±0.10 1.09± 0.12 0.58 
Fractional shortening (%) 19.40±5.58 20.83±7.99 0.65a 






End-systolic diameter (mm) 1.14±0.19 1.09±0.16 0.64 
End-diastolic diameter (mm) 1.44±0.16 1.35± 0.17 0.33 
Fractional shortening (%) 21.11±6.06 19.07±4.36 0.47a 
* Unpaired t-test used to compare means between groups
Parameter values given as mean ± s.d.
a. agree with the HOHF clinical findings
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